The sequencing of biologic agents used in metastatic colorectal cancer can affect the outcomes. We analyzed a multicenter registry to address a question that could not be answered using current clinical trial data. We found that whether or not patients had received previous bevacizumab, the effect of epidermal growth factor receptor antibodies in later lines of therapy was maintained. Background: The FIRE-3 [5-fluorouracil, folinic acid, and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line treatment colorectal cancer (CRC)] study reported that first-line FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab resulted in similar progression-free survival (PFS) but improved overall survival (OS). A potential explanation is that the initial biologic agent administered in metastatic CRC (mCRC) affects later line efficacy of the other treatments. We sought to test this hypothesis. Materials and Methods: We interrogated our mCRC registry (Treatment of Recurrent and Advanced Colorectal Cancer) regarding treatment and outcome data for RAS wild-type patients receiving epidermal growth factor receptor inhibitors (EGFRIs) in second and subsequent lines. Survival outcomes from the beginning of EGFRI use were determined as a function of previous bevacizumab use and the interval between ceasing bevacizumab and beginning EGFRI use. Results: Of 2061 patients, 222 eligible patients were identified, of whom 170 (77%) had received previous bevacizumab and 52 (23%) had not. PFS and OS from the start of EGFRIs did not differ by previous bevacizumab use (3.8 vs. 4.2 months; hazard ratio [HR], 1.12; P ¼ .81; 9.0 vs. 9.2 months; HR, 1.19; P ¼ .48, respectively) for the whole cohort or when analyzed by the primary tumor side (HR for left side, 1.07; P ¼ .57; HR for right side, 1.2; P ¼ .52). PFS was significantly shorter with right-sided primary tumors when the interval between bevacizumab and EGFRI use was < 6 versus > 6 months (median, 2.2 vs. 6 months; HR, 2.23; P ¼ .01) but not with left-sided tumors (median, 4.2 vs. 5.5 months; HR, 1.12; P ¼ .26). Conclusion: Previous bevacizumab use had no effect on the activity of subsequent EGFRIs. The apparent effect of time between biologic agents in right-sided tumors might reflect patient selection.
Introduction
Colorectal cancer (CRC) is a major health burden in Australia and worldwide and is the second leading cause of cancer-related deaths. 1 In the treatment of metastatic CRC (mCRC), questions regarding the optimal use of the available biologic options in the RAS wild-type population have driven recent randomized studies comparing the sequence of epidermal growth factor receptor inhibiting antibodies (EGFRIs), either cetuximab or panitumumab, and the antievascular endothelial growth factor (VEGF) antibody, bevacizumab. 2, 3 Such trials were conducted in the United States by the CALGB (Cancer and Leukemia Research Group) and in Germany and Austria (FIRE-3 [5-fluorouracil, folinic acid, and irinotecan (FOLFIRI) plus cetuximab versus FOLFIRI plus bevacizumab in first line treatment colorectal cancer (CRC)]).
Patients were randomized to either biologic agent in the first line and thereafter, whilst not mandated or planned for in the study protocols, patients could, at the investigators' discretion, cross over to the alternate biologic agent in second-line therapy. 2, 3 Although overall survival (OS) comparisons differed between these studies for the enrolled population, post hoc analyses defined a major effect of primary tumor side on survival outcomes. 4, 5 Specifically, adding an EGFRI to first-line chemotherapy improved survival in patients with left-sided RAS wild-type tumors. In contrast, across all firstline studies, patients with right-sided tumors did not benefit from EGFRI therapy. 6 In the FIRE-3 study, the first to study biologic sequencing in RAS wild-type mCRC, the initial choice of biologic agent did not affect first-line progression-free survival (PFS). However, improved OS was seen for patients randomized to initial cetuximab therapy. 3 Subsequently, it was shown that the PFS with second-line treatment with an EGFRI was shorter than the PFS for second-line bevacizumab, suggesting the choice of the initial biologic agent might affect the response to later use of the alternate biologic agent. 7 Although EGFRIs have shown proven activity in second and later treatment lines, these studies were conducted in an era with no or limited previous use of bevacizumab. 8, 9 A recent study randomized patients to continue bevacizumab or to receive an EGFRI after failure of first-line chemotherapy plus bevacizumab. The PFS and OS results both favored the continuation of bevacizumab. 10 In sum, these data suggest the possibility that the use of bevacizumab initially might alter the biology of the tumor cells, reducing their sensitivity to subsequent EGFRIs.
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Treatment and outcome data from large clinical registries might further inform our understanding of treatment sequencing, including whether previous bevacizumab use affects the efficacy of later EGFRIs. These analyses are of most value for those treatment sequences or scenarios that are not covered by clinical trials, including analyses of patients who did and did not receive bevacizumab with first-line chemotherapy and how this affected the benefit of EGFRIs in later treatment lines. We conducted the present analysis of patients entered into the Treatment of Recurrent and Advanced Colorectal Cancer (TRACC) registry. 12 In addition,
for patients who had received previous bevacizumab, we analyzed whether the time elapsed since ceasing bevacizumab had any effect on the efficacy of subsequent treatment lines. Multiple potential confounders were present in our analysis owing to the selection biases inherent to any registry. Thus, we examined the effect stratified by tumor side, given the differential effect of EGFRIs according to the primary tumor location.
Materials and Methods

Databases and Data Set
The TRACC registry captures data at the point of care, including careful annotation of baseline patient and tumor characteristics, treatments received, and patient outcomes. 12 We analyzed data related to clinical and pathologic factors known to affect survival outcomes, including patient demographic data, sites of metastatic disease, number of metastatic sites, side of primary tumor, Eastern Cooperative Oncology Group performance status, whether metastases were synchronous or metachronous, whether the primary was intact, and interval to progression during first-line treatment. Metachronous metastases were those defined as appearing 6 months after the diagnosis of the primary tumor. A right-sided primary was defined as any tumor proximal to the splenic flexure, and a left-sided primary was defined as a tumor of the splenic flexure or more distal colon or rectum.
The data from patients who received an EGFRI combined with chemotherapy or as a monotherapy in second or subsequent lines of treatment were included in the analysis. The specific antibody used (cetuximab or panitumumab) was recorded, but the data for both agents were combined, because they were considered to have equivalent efficacy. The interval to progression and OS data were calculated from the date of starting the EGFRI.
Initially, we analyzed the outcomes according to whether the patients had received any previous bevacizumab. The group that had received bevacizumab was then further split by the interval between the last bevacizumab dose and the first dose of the EGFRI (< 6 months vs. > 6 months). Analyses were then performed separately for patients with left-and right-sided primary tumors.
Statistical Analysis
PFS and OS, measured from the date the EGFRI was begun, were calculated using the Kaplan-Meier method and were compared using the log-rank test. Progression was judged by the local clinicians, and the imaging studies were not centrally reviewed.
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AntieEGFRIs Following Prior Bevacizumab in mCRC All statistics were calculated using SAS Enterprise guide, version 6.0, statistical software. Clinicopathologic differences between the groups were assessed using the c 2 and Wilcoxon rank sum tests for categorical and numerical variables, respectively. P values < .05 were considered statistically significant.
Ethical Approval
The TRACC registry received ethics approval at each participating institution to conduct combined analyses of de-identified patient data. The patients were not required to provide written informed consent. This specific project also received ethics approval (no. 2009.113) from the Melbourne Health Human Research Ethics Committee.
Results
Patients
We identified 222 patients who had received an EGFRI in second or later lines of therapy. Of these 222 patients, 170 (77%) had received previous bevacizumab ( Figure 1 ). Of the 170 bevacizumabtreated patients, 159 (92%) had received bevacizumab as part of their first-line therapy. The demographic data, Eastern Cooperative Oncology Group performance status, and disease and treatment characteristics are summarized in Table 1 . Generally, these were similar between the 2 groups, with the only significant difference being a longer time to progression with first-line treatment in the group receiving bevacizumab. Approximately 50% of patients in each group received chemotherapy, nearly always irinotecan based, combined with the EGFRI.
EGFRI Efficacy
Whether previous bevacizumab had been used did not affect PFS during EGFRI therapy ( Figure 2 ; median, 3.8 vs. 4.2 months, respectively; hazard ratio [HR], 1.12; P ¼ .81). Furthermore, no PFS difference with EGFRI therapy was seen when patients with left-and right-sided primary tumors were analyzed separately ( Figure 2B , c).
Because the median interval between stopping bevacizumab and beginning the EGFRI was 6 months, this cutoff was used to investigate any effect of the period between the last bevacizumab use on EGFRI efficacy, with 87 and 83 patients in the < 6-month and > 6-month groups, respectively. The characteristics of the patients in these 2 groups are listed in Table 2 . Patients in the > 6-month group had a longer time to first progression and fewer metastatic sites. Otherwise, the groups were similar. PFS with EGFRI therapy is displayed in Figure 3 . A significantly shorter PFS was seen for patients for whom the EGFRI was begun 6 months after ceasing bevacizumab (median PFS, 3.2 vs. 5.5 months; HR, 1.37; P ¼ .007). When analyzed by primary tumor side, no difference was noted for left-sided tumors (median PFS, 4.2 vs. 5.5 months; HR, 1.12; P ¼ .26). However, for those with right-sided tumors, the PFS was significantly shorter, with an interval of < 6 months (median PFS, 2.2 months vs. 6 months; HR, 2.23; P ¼ .01). When analyzed by primary tumor side using a 12-month cutoff, a similar, but nonstatistically significant, a trend was seen. For left-sided primary tumors, the median PFS was 4.6 and 5.5 months for 12 and > 12 months, respectively (P ¼ .32). For right-sided tumors, the median PFS was 2.4 and 6.2 months, respectively (P ¼ .17). However, the patient numbers were very small, with only 13 patients with a right-sided primary tumor having a > 12-month gap between bevacizumab and the EGFRI.
OS data, calculated from the date of beginning the EGFRI, stratified by previous bevacizumab use, is shown in Figure 4 . No difference was seen. The median OS was 9.0 versus 9.2 months in the previous and no previous bevacizumab groups, respectively (HR, 1.12; P ¼ .48).
Discussion
A number of studies exploring the optimal use and sequencing of first-line biologic therapy for RAS wild-type mCRC have produced unexpected results. The initial studies in which first-line bevacizumab and an EGFRI were combined and given with chemotherapy showed this combination to be detrimental. 13, 14 Therefore, subsequent studies have explored optimal biologic sequencing. The FIRE-3 study compared first-line FOLFIRI with either cetuximab or bevacizumab, with many patients, at the investigator's discretion, crossing to the alternate biologic agent for second-line therapy. No difference in PFS was seen; however, a significant OS benefit was found in favor of first-line cetuximab use. 3 One possible explanation is that the initial biologic choice affects the later activity of the other biologic agent. Consistent with this hypothesis were the observed differences in second-line PFS after patients crossed over to the alternate antibody in the FIRE-3 study. Specifically, second-line PFS favored bevacizumab-treated patients, suggesting the possibility that initial cetuximab either improved the efficacy of subsequent bevacizumab or initial bevacizumab reduced the subsequent efficacy of cetuximab. 7 Using registry data, we further explored the latter possibility, finding that the initial use of bevacizumab did not affect the later activity of an EGFRI, suggesting clinicians can use EGFRI therapy after bevacizumab without concern that treatment efficacy will be compromised. However, a longer interval (> 6 months) between bevacizumab and an EGFRI was associated with a longer PFS, a finding that was driven by patients with a right-sided primary tumor.
Our findings are consistent with those from other registry analyses, which have shown no effect of previous bevacizumab on later EGFRI efficacy. 15, 16 In contrast, prospective trials investigating the optimal second-line biologic agent after first-line bevacizumab have produced conflicting results. The PRODIGE-18 study (efficacy of chemotherapy, associated to either cetuximab or bevacizumab, in KRAS wild-type metastatic colorectal cancer patients with progressive disease after receiving first-line treatment with bevacizumab) randomized 133 KRAS exon 2 wild-type patients with progression after first-line chemotherapy plus bevacizumab to the alternate chemotherapy backbone plus either cetuximab or bevacizumab. A trend was found for both PFS and OS in favor of continuing bevacizumab that was maintained even when analyzing the subset of extended RAS and BRAF wildtype patients. 10 In this subgroup, the median PFS and OS was 8.2 and 21.1 months versus 5.7 and 12.6 months for those not continuing bevacizumab (P ¼ .1 for PFS). An analysis of outcome by primary tumor side has not yet been presented. However, the suggestion of superiority for continuation of bevacizumab into second-line therapy versus switching to an EGFRI was not supported by 2 further studies from Japan (West Japan Oncology Group 6210G) and the United States, both of which found no suggestion of a difference in outcome. Again, to the best of our knowledge, no analysis by primary tumor side is available from these studies. 17, 18 Another prospective, randomized phase II study conducted by the GISCAD group (Italian Group for the Study of Digestive Tract Cancer), in concordance with our findings, noted a significant interaction between the primary tumor side and the effect of the time elapsed between bevacizumab and cetuximab on outcomes. Patients were randomized to FOLFOX (folinic acid, 5-fluorouracil, and oxaliplatin) and then irinotecan/cetuximab, or the reverse sequence, after failure of first-line FOLFIRI/bevacizumab. A trend toward superior PFS and OS was noted in the FOLFOX followed by cetuximab/irinotecan sequence (ie, when a longer time gap between bevacizumab and cetuximab use had elapsed). This improvement was driven by patients with a rightsided primary tumor. 19 When analyzing these second-line studies of EGFRI efficacy, it should be remembered that benefit, as measured by PFS and OS, might not correlate, which has been seen in first-line treatment. 20 In that setting, a greater depth of response will influence the survival time after progression. This phenomenon has not been adequately addressed in later line studies.
International guidelines now recommend first-line EGFRI use combined with chemotherapy for left-sided RAS wild-type mCRC. Therefore, any interaction between first-line bevacizumab use and subsequent EGFRI efficacy will be most relevant for right-sided primary tumors, perhaps raising the importance of the findings from our analysis. 21 The specific sequence in which bevacizumab and EGFRI are used could affect treatment benefit owing to a biologic effect on malignant cells and/or the microenvironment in response to treatment with 1 biologic agent, which then affects the activity of the other. For example, in preclinical experiments, exposure to the anti-VEGF antibody bevacizumab results in increased serum-free VEGF levels, which in turn activate VEGFR receptor 2 and Stat-3, leading to cellular resistance to the EGFRI cetuximab.
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This might suggest a longer interval between bevacizumab and cetuximab is preferable, supported by our findings and those of the GISCAD study in patients with metastases from right-sided primary tumors.
The potential for a detrimental interaction between EGFRI and bevacizumab was first suggested by the findings of the CAIRO-2 and PACCE studies, which tested a combination of the 2 as part of first-line treatment for mCRC. 13, 14 In addition to an excess of adverse events with the biologic combination, a negative effect on survival outcomes was also evident. This observation suggests that a separation in time between biologic agent use might be important, prompting us to explore the effect of the time between bevacizumab use and EGFRI use. To the best of our knowledge, ours is the first study to report such data. We found no effect of timing on the efficacy of the EGFRI in left-sided tumors, a subset in which EGFRIs are expected to be active. However, patients with a right-sided primary tumor receiving the EGFRI > 6 months after bevacizumab had increased PFS on EGFRI therapy. Given that, we are not expecting much activity with EGFRI therapy in patients with a right-sided primary, 22 we would suggest this difference is mostly explained by confounding factors. For example, patients who received treatment after > 6 months likely had more indolent tumor biology and were destined to experience better outcomes, regardless of therapy. This is supported by the longer first-line PFS and fewer metastatic sites noted in the > 6-month group. Thus, the patients with right-sided tumors living long enough to receive treatment for > 6 months represent a distinct subset with a superior survival outcome even when receiving an inactive therapy. Regardless of the explanation, this finding highlights the challenges of defining the effect of the number of lines of treatment received. For example, an analysis of a large number of mCRC clinical trials found that patients who had received all active chemotherapy drugs had the best outcome, 23 with the investigators interpreting this finding to mean it was important to expose patients to as many drugs as possible. Our data suggest an alternative explanation for at least part of the observed survival effect-that the patients who live long enough (because of indolent disease biology) to receive all the drugs will have the best outcome, even if they were treated with an inactive drug such as an EGFRI for right-sided colon cancer. A similar confounder might be expected for left-sided tumors; however, we did not observe a time-based difference in this group. This might reflect the known prognostic differences between leftsided and right-sided tumors, with left-sided cancer patients having a more indolent biology; hence, a more mixed population of left-sided cancers might be included if a 6-month cutoff were used. To further explore this, we analyzed the data using a cutoff of 12 months but again found no efficacy difference for left-sided patients.
We acknowledge the limitations of our study, which was not prospective or randomized. Patients were treated at the clinician's discretion, with no preplanned sequence of therapy. Some patients received EGFRI monotherapy, others received EGFRI combined with chemotherapy, and we had insufficient numbers to further explore the data stratified by these subsets. As such, biases might exist, with undetected differences between the groups examined. Nonetheless, the registry data we analyzed are very detailed and meticulously completed for each patient. The electronic database possesses an automated checking system to ensure the validity of data as the data are entered. A major strength of our registry is that it captures the data from consecutive patients as they present to each institution and, thus, containing a true representation of the population with mCRC treated in daily practice, in contrast to randomized trials, in which the eligibility criteria lead to considerable patient selection.
Conclusion
Although considerable ongoing debate remains regarding the optimal sequence of biologic therapy in mCRC, our registry data do not support the hypothesis that first-line bevacizumab use negatively affects the subsequent efficacy of EGFRI therapy. An apparent relationship exists between the interval between bevacizumab and EGFRI therapy and the outcome for patients with right-sided primary tumors. However, the reasons are unclear and potentially resulted from confounding factors. 
Clinical Practice Points
Bevacizumab and the EGFR antibodies are biologic therapies that improve survival of patients with mCRC.
Patients with left-sided RAS wild-type primary tumors are most likely to benefit from treatment with an EGFRI; however, no predictive biomarkers for bevacizumab are available. Biologic agents are routinely combined with chemotherapy but should not be used concurrently.
The optimal sequence and timing of biologic use in mCRC is unknown and a subject of ongoing debate.
In an analysis of a comprehensive clinical registry, we found no evidence that previous bevacizumab use affects the activity of EGFRIs in later lines of therapy. Although a shorter gap (< 6 months) between bevacizumab and EGFRIs did not affect EGFRI activity in left-sided primary tumors, it was associated with a shorter PFS for those with rightsided primary tumors. When treating mCRC, EGFRIs can be used after bevacizumab in RAS wild-type tumors, without compromising their efficacy. When treating RAS wild-type right-sided primary tumors in later lines, our data support a better outcome if the EGFRI was begun > 6 months after ceasing bevacizumab, although this finding might be a result of confounding rather than reflecting any true biologic interaction.
